Study guide
Hypersensitivity, Anaphylaxis, and Infusion Reactions
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Hypersensitivity, Anaphylaxis, and Infusion Reactions
Key Takeaways Explain This Topic AI
The first action for a significant infusion reaction is to STOP the infusion, keep IV access open with compatible fluid, assess airway-breathing-circulation, and call for help.
Intramuscular epinephrine (adult dose 0.3 to 0.5 mg of 1 mg/mL into the anterolateral thigh) is the immediate life-saving treatment for anaphylaxis and must not be delayed for antihistamines or steroids.
Platinum agents (carboplatin, oxaliplatin) classically cause true IgE-mediated allergy on later cycles, while taxanes and monoclonal antibodies often cause first-dose infusion reactions during the first minutes.
Standard premedication for paclitaxel and many monoclonal antibodies includes a corticosteroid, an H1 antihistamine such as diphenhydramine, and an H2 blocker.
After a severe reaction, never restart the infusion without provider direction and protocol, and document the agent, timing, symptoms, vital-sign nadir, and treatment in detail.
Last updated: June 2026
Hypersensitivity, Anaphylaxis, and Infusion Reactions
Oncology patients receive many agents that trigger hypersensitivity or infusion reactions: monoclonal antibodies (rituximab, cetuximab), taxanes (paclitaxel, docetaxel), platinums (carboplatin, oxaliplatin), asparaginase, immunotherapy, blood products, and supportive drugs. Reactions may be IgE-mediated, cytokine-mediated, complement-mediated, or driven by excipients such as Cremophor (in solvent-based paclitaxel). The bedside response is the same regardless of mechanism: recognize, stop the exposure, assess severity, call for help, support airway and circulation, and give ordered rescue medications.
Timing and Drug-Specific Patterns
A key OCN distinction is timing . Reactions in the first few minutes of a first dose are typical of taxanes and monoclonal antibodies and are usually cytokine/infusion reactions, often manageable with rate reduction and premedication. True IgE-mediated allergy to platinum agents classically emerges after multiple prior uneventful cycles (often after 6 or more), because sensitization takes repeated exposure.
- Severity clue Nursing interpretation
- Localized itching or mild flushing Assess; slow or hold per protocol
- Generalized urticaria or rigors Higher concern; stop and notify
- Wheezing, stridor, throat tightness Airway emergency until proven otherwise
- Hypotension, syncope, confusion Possible shock; activate rapid response
- Recurrent symptoms hours later Possible biphasic reaction
Immediate Nursing Actions and Epinephrine
For any concerning reaction, stop the infusion first . Maintain IV access with compatible fluid, assess airway, breathing, circulation, vital signs, oxygen saturation, lung sounds, skin, and mental status. Call the provider, infusion-reaction team, or rapid response based on severity, position the patient supine with legs elevated if hypotensive, apply oxygen, and stay at the bedside.
Anaphylaxis is a clinical diagnosis - suspect it with acute onset of skin or mucosal involvement plus either respiratory compromise or hypotension, or two or more organ systems after a likely allergen. The single most important drug is intramuscular epinephrine : the adult dose is 0.3 to 0.5 mg of the 1 mg/mL (1:1000) concentration into the anterolateral thigh (vastus lateralis) , repeatable every 5 to 15 minutes. Antihistamines and corticosteroids are adjuncts only and must never delay epinephrine. Know where emergency medications and airway equipment are before you start any high-risk infusion.
Premedication and Prevention
Before administration, verify allergies, prior reactions, ordered premedications, baseline vital signs, and emergency readiness. Paclitaxel and many monoclonal antibodies require premedication with a corticosteroid (e.g., dexamethasone), an H1 blocker (diphenhydramine) , and an H2 blocker (famotidine) . Monitor most closely during the first dose, step-up dosing, rate increases, and any rechallenge. For blood products, follow the transfusion-reaction policy and stop the transfusion for any suspected serious reaction.
Rechallenge, Documentation, and Education
Do not restart an infusion after a significant reaction unless the provider and protocol direct it. Rechallenge and desensitization decisions weigh severity, symptom resolution, how essential the drug is, premedication, and infusion rate. Document the drug, dose, lot if required, premedications, start time, exact time symptoms began, full assessment, vital-sign nadir, every intervention, the patient's response, notifications, and education. This detail is load-bearing: the next team must know whether the event was mild flushing, cytokine-driven rigors, or true anaphylaxis.
Teach patients to report symptoms the instant they occur rather than hoping they pass - many patients stay quiet because they do not want to interrupt treatment. Be explicit: itching, chest tightness, throat or tongue symptoms, dizziness, shortness of breath, severe back pain, or swelling must be reported at once. After discharge, instruct patients to seek emergency care for delayed swelling, trouble breathing, recurrent hives, fainting, or worsening chest symptoms, which can signal a biphasic reaction hours later.
Differentiating Reaction Types
Cytokine-mediated infusion reactions feature fever, chills, rigors, hypotension, and hypoxia without classic urticaria. Allergic or anaphylactic reactions involve airway edema, wheezing, urticaria, GI cramping, and shock. The nurse does not need to name the mechanism before acting - severity and patient stability drive the response . Baseline assessment helps, because chronic dyspnea, anxiety, pain, or flushing may already be present before the infusion starts.
Monitoring, Transfusion Reactions, and Handoff
Monitor most intensively during the first 15 minutes of any high-risk infusion, since that is when most cytokine-driven reactions begin; many protocols specify a slow initial rate that is escalated only if tolerated.
For blood products , distinguish reaction types because management differs: an acute hemolytic reaction (fever, flank or back pain, dark urine, hypotension during the first minutes) is life-threatening and requires stopping the transfusion, keeping the line open with saline, and sending the unit and blood samples back; a febrile non-hemolytic reaction (isolated fever and chills) is less dangerous but still warrants stopping and assessing; and a mild allergic reaction (urticaria only) may be managed per policy with antihistamines. When in doubt, stop the transfusion - you can always restart, but you cannot undo a missed hemolytic reaction.
During handoff after any hypersensitivity event, include the exact sequence: premedications given, the infusion rate, the time symptoms began relative to the start, whether the drug was stopped, the vital-sign nadir (lowest blood pressure and oxygen saturation), respiratory findings, every medication administered including epinephrine doses and times, and whether symptoms fully resolved or recurred. This precise record is what guides future desensitization, rechallenge, premedication, or permanent-avoidance decisions, and it protects the patient across the entire treatment course.